Affiliation:
1. Washington University School of Medicine, St Louis, Missouri
2. Center for Tobacco Research and Intervention, School of Medicine and Public Health, University of Wisconsin, Madison
3. Division of Cardiothoracic Surgery, Department of Surgery, Washington University School of Medicine, St Louis, Missouri
4. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, Missouri
5. Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri
6. Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital, Washington University School of Medicine, St Louis, Missouri
Abstract
ImportanceIt is unclear whether cannabis use is associated with adverse health outcomes in patients with COVID-19 when accounting for known risk factors, including tobacco use.ObjectiveTo examine whether cannabis and tobacco use are associated with adverse health outcomes from COVID-19 in the context of other known risk factors.Design, Setting, and ParticipantsThis retrospective cohort study used electronic health record data from February 1, 2020, to January 31, 2022. This study included patients who were identified as having COVID-19 during at least 1 medical visit at a large academic medical center in the Midwest US.ExposuresCurrent cannabis use and tobacco smoking, as documented in the medical encounter.Main Outcomes and MeasuresHealth outcomes of hospitalization, intensive care unit (ICU) admission, and all-cause mortality following COVID-19 infection. The association between substance use (cannabis and tobacco) and these COVID-19 outcomes was assessed using multivariable modeling.ResultsA total of 72 501 patients with COVID-19 were included (mean [SD] age, 48.9 [19.3] years; 43 315 [59.7%] female; 9710 [13.4%] had current smoking; 17 654 [24.4%] had former smoking; and 7060 [9.7%] had current use of cannabis). Current tobacco smoking was significantly associated with increased risk of hospitalization (odds ratio [OR], 1.72; 95% CI, 1.62-1.82; P < .001), ICU admission (OR, 1.22; 95% CI, 1.10-1.34; P < .001), and all-cause mortality (OR, 1.37, 95% CI, 1.20-1.57; P < .001) after adjusting for other factors. Cannabis use was significantly associated with increased risk of hospitalization (OR, 1.80; 95% CI, 1.68-1.93; P < .001) and ICU admission (OR, 1.27; 95% CI, 1.14-1.41; P < .001) but not with all-cause mortality (OR, 0.97; 95% CI, 0.82-1.14, P = .69) after adjusting for tobacco smoking, vaccination, comorbidity, diagnosis date, and demographic factors.Conclusions and RelevanceThe findings of this cohort study suggest that cannabis use may be an independent risk factor for COVID-19–related complications, even after considering cigarette smoking, vaccination status, comorbidities, and other risk factors.
Publisher
American Medical Association (AMA)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Error in Figure;JAMA Network Open;2024-07-15